Helping melanoma patients decide whether to choose adjuvant high-dose interferon-α2b Journal Article
| Authors: | Hurley, K. E.; Chapman, P. B. |
| Article Title: | Helping melanoma patients decide whether to choose adjuvant high-dose interferon-α2b |
| Abstract: | High-dose interferon-α2b is a U.S. Food and Drug Administration- approved adjuvant treatment for stage III melanoma, and yet, because of its limited efficacy and well-known toxicity, it is not universally accepted by patients and oncologists. In this paper, we evaluate the benefits and risks of adjuvant high-dose interferon-α2b and try to provide a framework to help oncologists guide patients trying to decide whether to undergo adjuvant high-dose interferon therapy. ©AlphaMed Press. |
| Keywords: | survival; survival rate; clinical trial; fatigue; interferon; drug efficacy; risk benefit analysis; side effect; drug approval; cancer adjuvant therapy; cancer staging; drug megadose; alpha2b interferon; dacarbazine; melanoma; quality of life; liver toxicity; myalgia; food and drug administration; oncology; fever; health care cost; depression; cardiotoxicity; flu like syndrome; decision making; bone marrow toxicity; suicidal behavior; peginterferon; adjuvant treatment; interferon alfa-2b; risk-benefit |
| Journal Title: | The Oncologist |
| Volume: | 10 |
| Issue: | 9 |
| ISSN: | 1083-7159 |
| Publisher: | Oxford University Press |
| Date Published: | 2005-10-01 |
| Start Page: | 739 |
| End Page: | 742 |
| Language: | English |
| DOI: | 10.1634/theoncologist.10-9-739 |
| PUBMED: | 16249355 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 7" - "Export Date: 24 October 2012" - "CODEN: OCOLF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work